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Introduction {#sec1}
============

Gain-of-function mutations in the *KCNT1* gene are associated with severe, drug-resistant forms of childhood epilepsy ([@bib1], [@bib13]). Epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) were the first disorders found to be associated with *KCNT1*, with the more recently described Ohtahara syndrome ([@bib26]), West syndrome ([@bib32]), Lennox-Gastaut syndrome ([@bib16]), and sleep-related hypermotor epilepsy ([@bib4], [@bib38]). In addition to frequent seizures, patients may also present developmental delay and psychiatric and intellectual disabilities ([@bib10], [@bib21]). *KCNT1* encodes a sodium-activated potassium channel subunit, K~Na~1.1, which has previously been termed SLACK and Slo2.2 ([@bib18], [@bib43]). Similar to other potassium channels, the functional proteins are formed by a tetramer of subunits, each of which possesses six transmembrane alpha helices, a re-entrant pore loop between the fifth and sixth helix that forms the selectivity filter, and two intracellular regulation of conductance of potassium (RCK) domains ([@bib15]). K~Na~1.1-containing channels are expressed throughout the central nervous system ([@bib2], [@bib36]) and are believed to have a stabilizing effect on the membrane potential following sodium influx during neuronal excitation ([@bib3], [@bib5], [@bib12], [@bib23], [@bib31]). Virtually all epilepsy-associated *KCNT1* mutations increase channel activity, although why epilepsy should arise is not understood, since potassium channel opening is usually associated with a decrease in neuronal excitability. One proposed mechanism, based on studies of human stem cell-derived neurons harboring one such mutation, is that hyperexcitability can be caused by an enhanced sodium-dependent after-hyperpolarization, facilitating an increase in the rate of action potential firing ([@bib34]).

Quinidine is a class I antiarrhythmic agent, which exerts its effects by non-selectively inhibiting cardiac cation channels at micromolar concentrations. Notably, quinidine also inhibits K~Na~1.1 channels ([@bib42]), including those harboring epilepsy-causing mutations, at similar concentrations, leading to the hypothesis that quinidine could reverse the gain of function and treat *KCNT1*-associated epilepsy ([@bib28], [@bib29]). Limited improvement has been achieved in a small number of patients using quinidine therapy, but in the majority of cases it is ineffective ([@bib6], [@bib8], [@bib25], [@bib27], [@bib28], [@bib30]). The lack of selectivity and low potency of quinidine in inhibiting K~Na~1.1 channels, with IC~50~ values in the order of 0.1 mM ([@bib37], [@bib42]), in the central nervous system without significantly affecting cardiac function is a concern and limits the dosing levels of quinidine ([@bib30]). Moreover, there is still a paucity of information on the binding site and the mode of action of K~Na~1.1 inhibitors. Other reported inhibitors of K~Na~1.1 are bepridil ([@bib42]) and clofilium ([@bib7]), both of which also have inhibitory effects on cardiac cation channels. The identification of alternative drugs that better target K~Na~1.1 are therefore desired ([@bib28], [@bib29]). The mechanisms by which these three drugs inhibit potassium channels, hERG in particular, have been studied previously and involve direct block of the pore via the intracellular vestibule and are coordinated by aromatic side-chains, such as phenylalanine ([@bib19], [@bib20], [@bib24], [@bib33], [@bib41]).

With the development of direct electron detectors, more powerful microscopes, and improved data processing software, there has been an expansion of the use of cryo-electron microscopy (cryo-EM) and single particle analysis to determine high-resolution structures of membrane proteins ([@bib35]). Bypassing the need to crystallize membrane protein samples makes this approach particularly attractive. One of the first high-resolution ion channel structures determined by cryo-EM was the chicken K~Na~1.1 channel, initially described at 4.5 Å resolution ([@bib15]), with the inactive and activated conformations subsequently resolved to 4.3 and 3.8 Å, respectively ([@bib14]). The increase in resolution enables the generation of molecular models, which presents new opportunities that can be utilized in computer-aided drug discovery (CADD) or *in silico* drug design. To discover new therapies for rare disorders, such as those caused by *KCNT1* mutations, efficiencies of drug development cost and time are required ([@bib40]). Computer-aided approaches, such as virtual screening, can help reduce the need for functional screening of large compound sets by predicating which chemicals are likely to occupy a defined binding site ([@bib22]).

In this study, we used the cryo-EM-derived structures of the K~Na~1.1 channel to model quinidine binding *in silico*, having hypothesized that it blocks the channel pore, similar to its interaction with hERG. Having identified the intracellular pore vestibule as the likely site for known inhibitors to bind, we then conducted virtual high-throughput screening of a library of commercially available compounds with the view of identifying more potent and selective binders. We now report the identification of six diverse compounds that inhibit K~Na~1.1 more potently than the quinidine.

Results {#sec2}
=======

Identification of Inhibitor Binding Site in the K~Na~1.1 Channel Pore {#sec2.1}
---------------------------------------------------------------------

In the absence of potent and selective inhibitors of K~Na~1.1 potassium channels, we sought to use computational approaches to identify inhibitors with improved properties. To identify a region in the K~Na~1.1 structure to focus *in silico* screening, we first sought to identify how compounds known to inhibit the channel exert their effects. Hypothesizing that both quinidine and bepridil inhibit channels by occupying the inner pore vestibule we created a minimal structural model of the channel pore by removing the S1 to S4 and the cytosolic domains of the cryo-EM structures of the "closed" and "open" chicken K~Na~1.1 channel ([@bib14]). This left the S5, pore loop, and S6 of each subunit, which is highly conserved between chicken and human K~Na~1.1. Using automated procedures, both inhibitors were docked into the pore in its closed conformation at two distinct sites: in the vicinity of the equivalent positions of F346 and M354 in the S6 segment of the human isoform ([Figure 1](#fig1){ref-type="fig"}A). In contrast, using the model of the open conformation, quinidine and bepridil could only be docked to the site involving F346 ([Figure 1](#fig1){ref-type="fig"}A). To validate the docking, both residues (F346 and M354) of human K~Na~1.1 were mutated to isoleucine and serine ([Figures 1](#fig1){ref-type="fig"}B and 1C) and inhibition by quinidine and bepridil was evaluated further. Mutation of M354 had modest effects, with no significant effect on potency of quinidine, but the mutation of F346 to I346 reduced the potency approximately 10-fold ([Figure 2](#fig2){ref-type="fig"}). We found that mutating these pore residues, particularly F346, also increased channel activity, with respect to current amplitude and reduced current rectification ([Figures 1](#fig1){ref-type="fig"}B--1D). To exclude the possibility that increased channel activity was not the cause of the reduced efficacy of the inhibitors, for example, through preferential block of the closed state, their effects on a disease-causing gain-of-function mutation, Y796H ([@bib13]), was explored. This mutation causes an amino acid substitution in a K~Na~1.1 intracellular region distal to the pore domain and caused a large increase in K~Na~1.1 channel activity ([Figures 1](#fig1){ref-type="fig"}B--1D). In contrast to the pore mutants, quinidine inhibited this mutant channel with a 3-fold increase in potency ([Figure 2](#fig2){ref-type="fig"}B).Figure 1Molecular Docking of Inhibitors and Functional Analysis of Mutant K~Na~1.1 Channels Used in This Study(A) Docking of quinidine and bepridil (yellow) into the K~Na~1.1 pore domain, comprising the S5, P loop, and S6 of the closed and open conformational states (gray); side chains equivalent to F346 (magenta) and M354 (cyan) of the human K~Na~1.1 homolog are indicated.(B and C) (B) Representative whole-cell currents and (C) mean (±SEM, n = 5--9 cells) current-voltage plots from non-transfected (NT) HEK 293 cells and cells transfected with wild-type (WT), pore mutant (F346S, F346I, M354S, M354I), or disease-causing mutant (Y796H) K~Na~1.1.(D) Mean current amplitude at 0 mV from the data in (C); ∗p \< 0.05, ∗∗p \< 0.005 compared with WT, independent one-way ANOVA with Games-Howell post hoc test.Figure 2Concentration-Inhibition Analysis of Wild-Type and Mutant K~Na~1.1 Channels by Quinidine and Bepridil(A) Representative currents evoked by voltage ramps from cells expressing WT or mutant K~Na~1.1 with increasing concentrations of quinidine as indicated.(B) Mean (±SEM) concentration-inhibition plots for wild-type and mutant K~Na~1.1 channels in response to 3 μM to 1 mM quinidine. Mean (±SEM) IC~50~ for WT, 124.99 ± 34.52 μM (n = 5 cells); F346I, 736.08 ± 94.09 μM (n = 5); F346S, 1.23 ± 0.19 mM (n = 4); M354I, 99.23 ± 49.61 (n = 5); M354S, 247.16 ± 19.96 μM (n = 5); Y796H, 38.00 ± 12.89 μM (n = 5).(C) Mean (±SEM) concentration-inhibition plots for wild-type and mutant K~Na~1.1 channels in response to 0.3--100 μM bepridil. IC~50~ for WT, 6.36 ± 2.12 μM (n = 5); F346I, 35.91 ± 11.01 μM (n = 4); F346S, 23.43 ± 5.17 μM (n = 5).

Virtual Screening and Validation of K~Na~1.1 Inhibitors {#sec2.2}
-------------------------------------------------------

Having identified the internal vestibule, just below the selectivity filter, as the likely site for inhibitor binding, we used this region in the minimal pore structure of the open channel conformation to dock compounds using *in silico* screening and a diverse library of 100,000 drug-like molecules. This approach was complemented by computational identification of compounds with structural similarity to bepridil, the most potent of the known inhibitors of K~Na~1.1, and then also docking these compounds into the structure of the K~Na~1.1 channel pore. Both computational techniques resulted in a list of compounds, ranked by their docking score and predicted binding affinities. A selection of 17 compounds (details in [Table S1](#mmc1){ref-type="supplementary-material"}), based on their ranking and commercial availability, were then obtained and evaluated for their ability to inhibit human K~Na~1.1 channels expressed in HEK cells. At 10 μM, six of the compounds inhibited K~Na~1.1 currents by at least 40% and were selected for further analysis ([Figure 3](#fig3){ref-type="fig"}A). Initially, and to validate inhibition in the inner pore vestibule, we tested the ability of these compounds to inhibit F346S K~Na~1.1, which had showed reduced sensitivity to both quinidine and bepridil. At 10 μM, the degree by which F346S K~Na~1.1 was inhibited by each compound was reduced, compared with WT K~Na~1.1 ([Figure 3](#fig3){ref-type="fig"}A). Concentration-inhibition analysis ([Figures 3](#fig3){ref-type="fig"}B--3D) yielded mean IC~50~ concentrations ranging from 0.6 to 7.4 μM with WT K~Na~1.1. In comparison, quinidine and bepridil inhibited WT K~Na~1.1 with IC~50~ values in the order of 125 μM and 6.4 μM, respectively ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}D). Inspection of the inhibitors docked into the K~Na~1.1 pore domain suggests that binding involves both hydrophobic interactions with S6 pore-lining residues and hydrogen-bonding with P loop residues ([Figure 4](#fig4){ref-type="fig"} and [Table S1](#mmc1){ref-type="supplementary-material"}).Figure 3Functional Evaluation of Top-Scoring Molecules from *In Silico* Docking(A) Mean (±SEM, n = 3--4 cells) WT K~Na~1.1 conductance measured as the slope of the current evoked by depolarizing voltage ramps, relative to baseline, in the presence of 10 μM test compound; with those that were active (right of dashed line) counter-tested with F346S K~Na~1.1 pore mutant (∗p \< 0.05, ∗∗p \< 0.005, ∗∗∗p \< 0.0005, t test.).(B and C) (B) Representative traces and (C) mean (±SEM, n = 5--7 cells) concentration-inhibition plots for active inhibitors.(D) Summary table with mean (±SEM) potencies of compounds inhibiting WT and Y796H K~Na~1.1 (n = 5--7 cells). ∗p \< 0.05 versus potency with WT K~Na~1.1 (Student t test).See also [Table S1](#mmc1){ref-type="supplementary-material"}, [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.Figure 4Chemical Structures of Inhibitors (Magenta) and Their Docked Poses in the K~Na~1.1 Pore DomainSide chains at positions equivalent to the human isoform are indicated (pink): T314 in the P loop and F346 and M354 in the S6 segment of human K~Na~1.1. For clarity, the compounds are shown above each panel for the inhibitors analyzed in [Figure 3](#fig3){ref-type="fig"}.

The nature of the inhibition by these compounds was explored further. To be used therapeutically, K~Na~1.1 inhibitors would be required to inhibit channels that have epilepsy-causing amino acid substitutions. We therefore explored the potency of the inhibitors with Y796H K~Na~1.1 gain-of-function mutation. Each of the six compounds inhibited the mutant channels, but in this experiment BC7 and BC14 were significantly less potent ([Figures 3](#fig3){ref-type="fig"}B--3D and [S1](#mmc1){ref-type="supplementary-material"}). We also explored the importance of chemical groups in channel inhibition, using BC12 as an example, for which several analogues were commercially available. Each analogue failed to reduce WT K~Na~1.1 channel currents by more than approximately 10% at 10 μM and were deemed inactive ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Preliminary Toxicological Assessment of K~Na~1.1 Channel Inhibitors {#sec2.3}
-------------------------------------------------------------------

Finally, to anticipate toxicological effects of these compounds, should they or derivatives be developed further, we studied their effects on hERG potassium currents and in a cellular toxicity assay. From measurements of tail current amplitudes, 10 μM BC5, BC6, and BC7 almost completely inhibited hERG channels expressed in HEK 293 cells (\>80%, [Figures 5](#fig5){ref-type="fig"}A and 5B). In contrast, BC14 had a partial effect (approximately 45%) at the same concentration, whereas BC12 and BC13 were even less effective, reducing currents by approximately 10%--20%. In cytotoxicity assays, which involved exposing HEK 293 cells to compounds for 24 h, only BC7 exhibited a concentration-dependent reduction in cell viability, at concentrations of 1 μM and above ([Figure 5](#fig5){ref-type="fig"}C). With BC5, B6, and BC14, a reduction in cell viability was found at concentrations an order of magnitude higher than the IC~50~, whereas BC12 and BC14 had no effect at all concentrations tested, up to and including 100 μM ([Figure 5](#fig5){ref-type="fig"}C). Blasticidin (10 μg/mL) and DMSO (10% v/v) reduced cell viability in the order of 45% and 90%, respectively.Figure 5Preliminary Toxicological Assessment of K~Na~1.1 Channel Inhibitors(A) Representative hERG whole-cell currents recorded from a transfected HEK 293 cell in the absence (control) and presence of 10 μM inhibitor, as indicated.(B) Mean (±SEM, n = 3) tail current at −50 mV remaining in the presence of each inhibitor.(C) Cytotoxicity assays indicating mean (±SEM, n = 3) viability of HEK 293 cells using WST reagent following overnight exposure to inhibitor at the indicated concentrations, with 10 μM blasticidin and 10% v/v DMSO as positive controls; ∗p \< 0.05, ∗∗p \< 0.005, ∗∗∗p \< 0.0005, independent one-way ANOVA with Dunnett\'s post hoc test.

Discussion {#sec3}
==========

Analysis of compounds identified as potential K~Na~1.1 inhibitors by *in silico* docking yielded six previously unknown inhibitors, each more potent than quinidine that has been trialed clinically as a stratified treatment for *KCNT1*-associated epilepsy. These inhibitors are structurally diverse and there is no clear pharmacophore, although BC6 and BC7 are among the scaffolds with structural similarity to bepridil. We propose that each of these compounds, in addition to quinidine and bepridil, inhibits the channel by blocking the pore via the intracellular vestibule. This is indicated by the reduced efficacy of each compound with the F346S pore mutation, and which is likely to be independent of the increased channel activity caused by the mutation, since with quinidine there was no similar loss of efficacy with Y796H, an epilepsy-causing mutation distal from the pore. The effects of mutations of F346 are somewhat modest, yielding a 10-fold decrease in potency, compared with WT K~Na~1.1, suggesting that other interactions are necessary, but are consistent with the hypothesis that inhibitors block the channel by occupying the inner vestibule of the pore. This residue is also at the equivalent position in the S6 segment as F656 in hERG that co-ordinates inhibitor binding of quinidine, bepridil, and clofilium ([@bib19], [@bib24], [@bib33]). This mode of action requires the inhibiting compound to traverse the plasma membrane and enter the pore via the cytoplasm. It is noteworthy that each of the compounds tested that had a calculated logP (cLogP) value of 3.2 or less did not exhibit inhibition of K~Na~1.1, and this may have been a result of poor membrane permeability. By using a model of the ion channel pore that is putatively in the open conformation, we had anticipated that inhibitors identified through docking would achieve similar or even higher potency with the Y796H mutant K~Na~1.1, but this was not always the case. It is possible that the apparent decrease in potency of some of the compounds with Y796H may be attributed to the high level of basal channel activity with this mutant channel and incomplete series resistance compensation. This could underestimate channel inhibition at the lower concentrations and increase variability. The increase in potency of quinidine with Y796H, relative to WT K~Na~1.1, however, is consistent with previous studies of other gain-of-function mutations ([@bib37]).

It may have been possible to obtain inhibitors by testing compounds identified through computational tools to have structures similar to the known inhibitors, quinidine, bepridil, and clofilium, but without using molecular docking. The risk with this approach is that the compounds may also have similar potency in inhibiting cardiac ion channels, which would preclude their further development. Indeed, this is what we found with BC6 and BC7, which both almost completely inhibited hERG currents at 10 μM. Instead, by docking a diverse library, we were able to identify compounds that were structurally distinct from the known inhibitors and that included some that had little effect on hERG at 10 μM. Together, this highlights the importance of screening a wide range of compounds, which in our approach employed virtual screening using computational approaches instead of a high-throughput cell-based functional screen. Other sites in the channel protein could potentially be used to target molecular docking and virtual screening, which may enhance K~Na~1.1 selectivity over other ion channels, but there is presently a lack of understanding of how other K~Na~1.1 domains could be targeted pharmacologically to modulate channel function.

Although the cryo-EM structures indicate that activation by sodium involves an expansion of the intracellular pore vestibule ([@bib14]), functional experiments with this and the closely related K~Na~1.2 and K~Ca~1.1 (BK~Ca~) channels point to the selectivity filter and proximal hydrophobic residues, rather than an S6 helix bundle, as the location of the channel gate ([@bib9], [@bib11], [@bib17], [@bib39]). This means that the inhibitors described here block at the channel gate and this should be a mode of inhibition that is efficacious with virtually all clinical gain-of-function mutations, independent of the mechanism by which increased open probability is achieved, rather than an inhibitor that binds to modulatory sites. An exception, however, may be F346L that was identified in a patient with EIMFS ([@bib27]), which, based on our findings with mutations generated at this site in the pore, may have reduced inhibitor sensitivity. Indeed, it was found that F346L K~Na~1.1 channels expressed in *Xenopus* oocytes were resistant to block by 300 μM quinidine ([@bib27]), although the pharmacological effects of quinidine on channels containing a mixture of F346L and wild-type subunits, to mimic the heterozygous disorder, has not been explored.

Notwithstanding our preliminary efforts to characterize the potential toxicity of these inhibitors by studying inhibition of hERG channel currents and the effects in cell viability assays, we are unable to make any statement regarding their selectivity or safety ahead of any *in vitro* or *in vivo* investigation. Since the computational approach was based on the inhibition by quinidine and bepridil, one might expect a similar range of ion channels to be inhibited by the compounds described here. However, the low level of inhibition of hERG at 10 μM by BC12 and BC13 suggests that across the compounds there may be varying levels of selectivity, which could be further improved by synthesis and analysis of derivative compounds and testing their effects on a range of different cation channels. We do note, however, the characteristics of pan-assay interference (PAINS) in compounds BC6, BC7, and BC13, owing to the presence of the conjugated carbonyl group, meaning there may be non-specific effects in other functional assays. The lack of effects of the four analogues of BC12 tested demonstrates the potential for generating an inhibitor pharmacophore from this compound; thus, these may provide starting points for the development of more potent inhibitors.

The generation of high-resolution structural data by cryo-electron microscopy and single particle analysis has had a significant impact in structural biology. Importantly, circumventing the need to crystallize samples means that membrane proteins are more amenable to analysis, and also that human proteins, rather than homologs from prokaryotes and lower eukaryotes, now feature more prominently. This means that, for *in silico* analysis and drug discovery, target proteins very close to human, if not the human protein itself, can be utilized. The pore domain of the chicken K~Na~1.1 subunit, however, is virtually identical to that of the human homolog, and we demonstrate its suitability for *in silico* docking experiments to provide potential inhibitors to characterize using a functional assay. Our study, in addition to identifying K~Na~1.1 inhibitors from a compound library, provides a further example of the use of cryo-electron microscopy-generated membrane protein structural data in identifying new small molecule inhibitors through a structure-based discovery approach.

Limitations of the Study {#sec3.1}
------------------------

A structure of the human K~Na~1.1 channel was not available, so we employed that of the chicken homolog. The channel domain used for the docking experiments is highly conserved between chicken and human K~Na~1.1, and the specific residues discussed are conserved. By restricting the docking experiments to the intracellular pore vestibule of the channel, to decrease computational complexity, we disregarded potential interactions of compounds with other parts of the protein.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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